Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model

Eun Jung Park, Junhyun Ahn, Sang Won Gwak, Kyung Su Park, Seung Hyuk Baik, Sung Joo Hwang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.

Original languageEnglish
Pages (from-to)3185-3192
Number of pages8
JournalAnnals of surgical oncology
Volume25
Issue number11
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

oxaliplatin
Area Under Curve
Lipids
Drug Therapy
Water
Mitomycin
Peritoneum
Pharmaceutical Preparations
Glucose
Dialysis Solutions
Peritoneal Dialysis
Antineoplastic Agents
Solubility
Sprague Dawley Rats

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{5753db6d5e9f4250bc5c434257960aef,
title = "Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model",
abstract = "Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal {\circledR} PD-2 peritoneal dialysis solution, 5{\%} dextrose solution and 20{\%} lipid solution (Lipision {\circledR} ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal {\circledR} (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5{\%} dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.",
author = "Park, {Eun Jung} and Junhyun Ahn and Gwak, {Sang Won} and Park, {Kyung Su} and Baik, {Seung Hyuk} and Hwang, {Sung Joo}",
year = "2018",
month = "10",
day = "1",
doi = "10.1245/s10434-018-6628-x",
language = "English",
volume = "25",
pages = "3185--3192",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "11",

}

Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy : Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model. / Park, Eun Jung; Ahn, Junhyun; Gwak, Sang Won; Park, Kyung Su; Baik, Seung Hyuk; Hwang, Sung Joo.

In: Annals of surgical oncology, Vol. 25, No. 11, 01.10.2018, p. 3185-3192.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy

T2 - Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model

AU - Park, Eun Jung

AU - Ahn, Junhyun

AU - Gwak, Sang Won

AU - Park, Kyung Su

AU - Baik, Seung Hyuk

AU - Hwang, Sung Joo

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.

AB - Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.

UR - http://www.scopus.com/inward/record.url?scp=85050356622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050356622&partnerID=8YFLogxK

U2 - 10.1245/s10434-018-6628-x

DO - 10.1245/s10434-018-6628-x

M3 - Article

C2 - 30027459

AN - SCOPUS:85050356622

VL - 25

SP - 3185

EP - 3192

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -